At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CNTX Context Therapeutics Inc.
Trading 05-18 10:15:58 EDT
2.19
+0.03
+1.39%
High2.22Low2.17Vol72.46K
Open2.17D1 Closing2.16Amplitude2.30%
Mkt Cap201.22MTradable Cap87.32MTotal Shares91.88M
T/O158.79KT/O Rate0.18%Tradable Shares39.87M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Context Therapeutics Secures Full Rights to Antibody Assets
TIPRANKS  ·  19:20
Context Therapeutics Secures Full Rights to Antibody Assets
Context Therapeutics enters license agreement amendment with BioAtla
TIPRANKS  ·  18:54
Context Therapeutics enters license agreement amendment with BioAtla
Context Therapeutics pays USD 6.5 million to buy out CT-202 milestones, royalties
Reuters  ·  18:47
Context Therapeutics pays USD 6.5 million to buy out CT-202 milestones, royalties
Context Therapeutics Enters Into License Agreement Amendment With Bioatla for Ct-202
THOMSON REUTERS  ·  18:45
Context Therapeutics Enters Into License Agreement Amendment With Bioatla for Ct-202
Context Therapeutics - Announces Buyout of Ct-202 Future Milestones and Royalties
THOMSON REUTERS  ·  18:45
Context Therapeutics - Announces Buyout of Ct-202 Future Milestones and Royalties
Context Therapeutics: Amendment Removes All Future Milestone and Royalty Obligations Owed by Company for Ct-202
THOMSON REUTERS  ·  18:45
Context Therapeutics: Amendment Removes All Future Milestone and Royalty Obligations Owed by Company for Ct-202
Context Therapeutics - to Pay $4.5 Mln Upfront and $2.0 Mln by Aug 1, 2026 for Ct-202 License
THOMSON REUTERS  ·  18:45
Context Therapeutics - to Pay $4.5 Mln Upfront and $2.0 Mln by Aug 1, 2026 for Ct-202 License
Analysts Are Bullish on These Healthcare Stocks: Tenaya Therapeutics (TNYA), Context Therapeutics (CNTX)
TIPRANKS  ·  05-10
Analysts Are Bullish on These Healthcare Stocks: Tenaya Therapeutics (TNYA), Context Therapeutics (CNTX)
Context Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Reuters  ·  05-08
Context Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Context Therapeutics (CNTX) Gets a Buy from Guggenheim
TIPRANKS  ·  05-07
Context Therapeutics (CNTX) Gets a Buy from Guggenheim
Analysts Are Bullish on These Healthcare Stocks: Mineralys Therapeutics, Inc. (MLYS), Context Therapeutics (CNTX)
TIPRANKS  ·  05-07
Analysts Are Bullish on These Healthcare Stocks: Mineralys Therapeutics, Inc. (MLYS), Context Therapeutics (CNTX)
Context Therapeutics Q1 net loss widens 90% to $8.68 million
Reuters  ·  05-07
Context Therapeutics Q1 net loss widens 90% to $8.68 million
Context Therapeutics Q1 net loss widens on higher R&D costs
Reuters  ·  05-07
Context Therapeutics Q1 net loss widens on higher R&D costs
Context Therapeutics - Cash and Cash Equivalents of $54.5 Mln as of March 31, 2026 Expected to Fund Operations Into Mid-2027
THOMSON REUTERS  ·  05-07
Context Therapeutics - Cash and Cash Equivalents of $54.5 Mln as of March 31, 2026 Expected to Fund Operations Into Mid-2027
Context Therapeutics Inc. Q1 Basic EPS USD -0.09
THOMSON REUTERS  ·  05-07
Context Therapeutics Inc. Q1 Basic EPS USD -0.09
Context Therapeutics settles governance lawsuit with mootness fee
TIPRANKS  ·  05-02
Context Therapeutics settles governance lawsuit with mootness fee
Context Therapeutics litigation ends with $850,000 mootness fee paid by provider
Reuters  ·  05-02
Context Therapeutics litigation ends with $850,000 mootness fee paid by provider
Context Therapeutics Inc expected to post a loss of 12 cents a share - Earnings Preview
Reuters  ·  04-30
Context Therapeutics Inc expected to post a loss of 12 cents a share - Earnings Preview
Context Therapeutics announces annual shareholder meeting
Reuters  ·  04-18
Context Therapeutics announces annual shareholder meeting
Neogen names Jennifer Evans Stacey chief legal, compliance officer, board secretary
Reuters  ·  04-08
Neogen names Jennifer Evans Stacey chief legal, compliance officer, board secretary

Introduction

Company Name.
Context Therapeutics Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors in the United States. It develops CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Issue price:
--